Superficial laser vulvectomy. V. Surgical debulking is enhanced by adjuvant systemic interferon.
Skillful laser ablation can remove any volume of human papillomavirus-associated vulvar disease but cannot prevent reactivation of the surrounding latent viral reservoir during postoperative healing. Conversely, interferon and 5-fluorouracil are relatively ineffective as primary therapies in clearing bulky lesions. In this study of 71 assessable patients, topical 5-fluorouracil and systemic interferon injections were used postoperatively. Success rates within the adjuvant 5-fluorouracil and laser alone arms were essentially the same (9 of 18 vs 8 of 20). In contrast, outcome in the interferon group was significantly better than that for the other two arms combined (27 of 33 [82%] vs 17 of 38 [45%]; chi 2 10.31; p less than 0.002). Moreover, 18 of 21 failures (86%) in the first two arms and 3 of 6 failures (50%) in the interferon arm were "rescued" from the need for a second laser surgical procedure by crossover to either the 1 or 3 MIU interferon regimen. Results from this open-label, randomized clinical trial suggest that even a relatively low dose of recombinant interferon, used in combination with effective surgical debulking, can markedly reduce the risk of postoperative recurrence.
Sinai Hospital of Detroit, MI.
R
R
Reid
M D
MD
Greenberg
D J
DJ
Pizzuti
K H
KH
Omoto
L H
LH
Rutledge
W
W
Soo
D000287:Administration, Topical; D003218:Condylomata Acuminata / Q000473:pathology / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D053685:Laser Therapy; D027383:Papillomaviridae; D014412:Tumor Virus Infections / Q000473:pathology / Q000628:therapy*; D014844:Vulva / Q000601:surgery*
D007372:Interferons; D005472:Fluorouracil